About these slide decks and video commentaries
This series of freely downloadable, state-of-the-art slide decks has been developed to complement and build on the content of the current Back to Basics section of the Lp(a) Forum. Back to Basics was designed to introduce Forum members to the growing recognition of Lp(a) as an important, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, even when LDL-cholesterol levels are low.
These new Back to Basic slide decks take viewers from early concepts about the science of Lp(a), through evidence-based knowledge about its role in ASCVD and aortic valve stenosis, to practical implications for Lp(a) testing and patient care in daily practice.
Alongside each slide deck, a member of the Lp(a) Forum’s Editorial Board of internationally recognised experts from the scientific and clinical communities presents a video commentary. This reflects their own specialist insights into the specific aspects of Lp(a) research included in the slide deck, together with their current and potential future application in primary and secondary care.
Lilly has provided arms’ length sponsorship funding for the Lp(a) Forum Back to Basics Educational Resources but has had no influence or control over the content.
First slide deck and video commentary now available
What is Lp(a)?
This slide deck is a guide to the structure, function, production and clearance of Lp(a), its genetics, atherogenicity, interaction with the arterial wall, impact on plaque progression, and proatherogenic, proinflammatory and prothrombotic activities.
Commentary by: Professor John Chapman, Pitié-Salpetrière University Hospital, INSERM, Paris France
Coming next – more slide decks and commentaries from this series…
- Elevated Lp(a): Who is at risk? A case study based overview of the epidemiology of Lp(a) elevation including the importance of age, gender, genetics and ethnicity in identifying patients at risk.
- Lp(a) testing. Practical information about tests, measurement units, normal and elevated levels, and guideline recommendations for testing.
- Lp(a) and cardiovascular disease. Current understanding of the impact of elevated Lp(a) on risk of coronary heart disease, ischaemic stroke, peripheral artery disease, heart failure, aortic valve stenosis, and mitral valve stenosis, and related events and mortality.
- CV risk assessment in primary care: What does Lp(a) add? A review of latest evidence about the impact of including Lp(a) in CV risk scores and Lp(a) atherogenicity compared to other lipoproteins.
